Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.33 |
| ▸ | FNTA | P49354 | 3/20 | 0.33 |
| ▸ | FNTB | P49356 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1389755 | 1.00 | GPBAR1 (0.36) | GPBAR1FFAR1ADRB3ADRB1P2RX3 | |
| SCHEMBL364646 | 0.93 | P2RX3 (0.37) | GPBAR1FFAR1ADRB3ADRB1P2RX3 | |
| SCHEMBL364647 | 0.93 | P2RX3 (0.37) | GPBAR1FFAR1ADRB3ADRB1P2RX3 | |
| SCHEMBL1389959 | 0.90 | FFAR1 (0.35) | GPBAR1FFAR1P2RX3 | |
| SCHEMBL1389962 | 0.90 | FFAR1 (0.35) | GPBAR1FFAR1P2RX3 | |
| SCHEMBL368539 | 0.90 | FFAR1 (0.37) | FFAR1ADRB3ADRB1P2RX3FNTA | |
| SCHEMBL364385 | 0.89 | P2RX3 (0.41) | GPBAR1ADRB3P2RX3 | |
| SCHEMBL364384 | 0.89 | P2RX3 (0.41) | GPBAR1ADRB3P2RX3 | |
| SCHEMBL1389988 | 0.86 | GPBAR1 (0.46) | GPBAR1FFAR1 | |
| SCHEMBL1389987 | 0.86 | GPBAR1 (0.46) | GPBAR1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | claimed |
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, GPR119, ADRB1 | GPBAR1 1/4885FFAR1 14/4885ADRB3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.